Clinical Trials Browser

Recruiting × Colorectal Neoplasms × Cetuximab × Clear all

NCT06102902 2026-03-18

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06917079 2026-03-18

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT07223047 2026-03-17

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05253651 2026-03-16

MOUNTAINEER-03

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06179160 2026-03-16

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06445062 2026-03-13

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 1/2 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT05985954 2026-03-12

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05239741 2026-03-10

MK-3475-C66

Phase 3 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06835569 2026-03-09

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07020221 2026-03-09

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06412198 2026-03-06

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04929223 2026-03-03

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05863195 2026-03-02

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06447662 2026-02-25

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Phase 1 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07397338 2026-02-09

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07349537 2026-02-04

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06358430 2026-01-15

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07318805 2026-01-06

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05959356 2025-12-17

CEIL

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07216105 2025-12-17

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07259590 2025-12-02

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07253896 2025-11-28

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05200442 2025-11-05

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05576896 2025-10-20

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04776655 2025-10-02

LIBImAb

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04956640 2025-09-25

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Phase 1/2 Recruiting

GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05706779 2025-09-02

NEORAF

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06978400 2025-05-18

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06763029 2025-02-27

VICPROIRI

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06640166 2025-02-12

ECLYPse

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT06411600 2024-11-08

BRAVE

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03874026 2024-11-07

CIFRA

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06603376 2024-09-19

Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06547203 2024-08-09

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06321081 2024-03-20

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06225622 2024-03-19

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05962502 2023-08-31

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05797467 2023-05-24

Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04673955 2022-09-29

BERING-CRC

Gastrointestinal

Colorectal Neoplasms